Literature DB >> 19733548

Inhibition of hepatitis B virus replication with linear DNA sequences expressing antiviral micro-RNA shuttles.

Saket Chattopadhyay1, Abdullah Ely, Kristie Bloom, Marc S Weinberg, Patrick Arbuthnot.   

Abstract

RNA interference (RNAi) may be harnessed to inhibit viral gene expression and this approach is being developed to counter chronic infection with hepatitis B virus (HBV). Compared to synthetic RNAi activators, DNA expression cassettes that generate silencing sequences have advantages of sustained efficacy and ease of propagation in plasmid DNA (pDNA). However, the large size of pDNAs and inclusion of sequences conferring antibiotic resistance and immunostimulation limit delivery efficiency and safety. To develop use of alternative DNA templates that may be applied for therapeutic gene silencing, we assessed the usefulness of PCR-generated linear expression cassettes that produce anti-HBV micro-RNA (miR) shuttles. We found that silencing of HBV markers of replication was efficient (>75%) in cell culture and in vivo. miR shuttles were processed to form anti-HBV guide strands and there was no evidence of induction of the interferon response. Modification of terminal sequences to include flanking human adenoviral type-5 inverted terminal repeats was easily achieved and did not compromise silencing efficacy. These linear DNA sequences should have utility in the development of gene silencing applications where modifications of terminal elements with elimination of potentially harmful and non-essential sequences are required.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19733548     DOI: 10.1016/j.bbrc.2009.09.004

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  9 in total

1.  Exogenous DNA Loading into Extracellular Vesicles via Electroporation is Size-Dependent and Enables Limited Gene Delivery.

Authors:  Tek N Lamichhane; Rahul S Raiker; Steven M Jay
Journal:  Mol Pharm       Date:  2015-09-23       Impact factor: 4.939

2.  Progress in the use of RNA interference as a therapy for chronic hepatitis B virus infection.

Authors:  Marc S Weinberg; Patrick Arbuthnot
Journal:  Genome Med       Date:  2010-04-28       Impact factor: 11.117

Review 3.  Current translational and clinical practices in hematopoietic cell and gene therapy.

Authors:  David L Digiusto; Hans-Peter Kiem
Journal:  Cytotherapy       Date:  2012-08       Impact factor: 5.414

Review 4.  MicroRNAs may solve the mystery of chronic hepatitis B virus infection.

Authors:  Ying-Feng Wei; Guang-Ying Cui; Ping Ye; Jia-Ning Chen; Hong-Yan Diao
Journal:  World J Gastroenterol       Date:  2013-08-14       Impact factor: 5.742

5.  Expression and Characterization of the RKOD DNA Polymerase in Pichia pastoris.

Authors:  Fei Wang; Shuntang Li; Hui Zhao; Lu Bian; Liang Chen; Zhen Zhang; Xing Zhong; Lixin Ma; Xiaolan Yu
Journal:  PLoS One       Date:  2015-07-02       Impact factor: 3.240

Review 6.  MicroRNAs as Important Players in Host-hepatitis B Virus Interactions.

Authors:  Bouchra Kitab; Hanane Salih Alj; Sayeh Ezzikouri; Soumaya Benjelloun
Journal:  J Clin Transl Hepatol       Date:  2015-06-15

7.  Inactivation of hepatitis B virus replication in cultured cells and in vivo with engineered transcription activator-like effector nucleases.

Authors:  Kristie Bloom; Abdullah Ely; Claudio Mussolino; Toni Cathomen; Patrick Arbuthnot
Journal:  Mol Ther       Date:  2013-07-25       Impact factor: 11.454

Review 8.  New insights on the role of epigenetic alterations in hepatocellular carcinoma.

Authors:  Maddalena Frau; Claudio F Feo; Francesco Feo; Rosa M Pascale
Journal:  J Hepatocell Carcinoma       Date:  2014-06-12

9.  Inhibition of hepatitis B virus replication by helper dependent adenoviral vectors expressing artificial anti-HBV pri-miRs from a liver-specific promoter.

Authors:  Mohube Betty Mowa; Carol Crowther; Abdullah Ely; Patrick Arbuthnot
Journal:  Biomed Res Int       Date:  2014-06-05       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.